Journey Medical (DERM) Return on Capital Employed (2021 - 2026)

Journey Medical has reported Return on Capital Employed for 6 years, with the latest figure at 11.48% in Q1 2026.

• For the quarter ending Q1 2026, Return on Capital Employed rose 483.0% year-over-year to 11.48%; the trailing twelve-month figure through Mar 2026 stood at 11.48% (up 483.0% YoY), and the FY2025 full-year result was 16.35%, up 1518.0% from the prior year.
• Return on Capital Employed for Q1 2026 stood at 11.48%, up from 15.58% in the prior quarter.
• The five-year high for Return on Capital Employed was 6.69% in Q2 2024, with the low at 251.26% in Q2 2023.
• Historically, Return on Capital Employed has averaged 51.82% across 5 years, with a median of 37.0% in 2024.
• Annual changes were most pronounced in 2023 — Return on Capital Employed sank 19918 bps — and 2024, when it jumped 25795 bps.
• Journey Medical's Return on Capital Employed stood at 69.1% in 2022, then surged by 90 bps to 7.02% in 2023, then slumped by 427 bps to 37.0% in 2024, then jumped by 58 bps to 15.58% in 2025, then increased by 26 bps to 11.48% in 2026.
• The last three Return on Capital Employed figures came in at 11.48% (Q1 2026), 15.58% (Q4 2025), and 12.64% (Q3 2025), per Business Quant data.